Gluetacs Therapeutics has reported filing an Investigational New Drug (IND) application for its first molecular glue degrading agent with the Center for Drug Evaluation in China. The company, which specializes in the development of small molecule drugs via protein degradation technology, has also secured an undisclosed amount of investment from existing investor Grains Valley Venture Capital.
Company Overview and Expertise
Founded in 2020 by academician Jiang Biao, former director of the Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, and Dr. Yang Xiaobao, formerly with the Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Gluetacs Therapeutics is focused on advancing small molecule drugs through innovative protein degradation technology. The team at Gluetacs is highly experienced in AI-driven rational design and virtual screening of degraders, high-throughput digital cell screening, optimization of oral druggability, quantitative proteomics verification, and in vivo pharmacology and toxicology verification.
Future Outlook
The IND filing for Gluetacs’ molecular glue degrading agent marks a significant step forward in the company’s development pipeline. With the support of Grains Valley Venture Capital, Gluetacs is well-positioned to advance its technology and bring innovative protein degradation therapies to the market.-Fineline Info & Tech
